No Carolina / NY / Florida
Ph: 561.316.3330

Revival Health Inc. Announces 9 Mil FDA EUA Authorized COVID-19 Rapid At-home Tests

Available December 2021

Summation

  •   Uniquely, the test is authorized for use as a single test with or without symptoms in contrast to other home tests which require two tests within a two-to-three-day period.
  •   The test is authorized for self-testing by individuals aged 14 years and older, or with adult-collected nasal swabs from children as young as 2 years old.
  • The COVID-19 Antigen Home Test is a simple nasal swab test which will be available for purchase without prescription.

Revival Health Inc. (Revival), a leading global medical device manufacturer, announced the availability of over 9 million units per month of the EUA authorized COVID-19 rapid at-home tests. The company has stepped up production to produce over 9 million tests in December, 10 million in January and up to 20 million in February. The COVID-19 Antigen Home Test provides:

  • Easy and Affordable
  • Highly Accurate Nasal Swab Test
  • Quick Results in 15 minutes
  • Safe for children as young as 2 years old
  • For use with and without symptoms

The COVID-19 Antigen Home Test is a simple nasal swab test which will be available for purchase without prescription.  The test is authorized for self-testing by individuals aged 14 years and older, or with adult-collected nasal swabs from children as young as 2 years old.  Uniquely, the test is authorized for use as a single test with or without symptoms in contrast to other home tests which require two tests within a two-to-three-day period.

“We are investing heavily and pulling out all the stops to get Americans maximum protection as we face this new Omicron COVID variant through the holiday season. It is our mission to make healthcare more affordable, accessible, and easy to use. Our development and investments in COVID-19 testing moves us one step closer to this achievement,” states Jenny Yang, Chief Revenue Officer at Revival Health.

The test will be available for shipping as soon as December 20, 2021.

Other FDA News of Interest

Justice Department and FDA Announce Federal Multi-Agency Task Force to Curb the Distribution and Sale of Illegal E-Cigarettes

"Unauthorized e-cigarettes and vaping products continue to jeopardize the health of Americans – particularly children and adolescents – across the country," said Acting Associate Attorney General Benjamin C. Mizer. "This interagency Task Force is dedicated to protecting Americans by combatting the unlawful sale and distribution of these products. And the establishment of this Task Force makes clear that vigorous enforcement of the tobacco laws is a government-wide priority."

Tris Pharma Receives U.S. FDA Approval for Once-Daily ONYDA XR (clonidine hydrochloride) Extended-Release Oral Suspension, the First-and-Only Liquid Non-Stimulant ADHD Medication

ONYDA XR is indicated for the treatment of ADHD as monotherapy or as adjunctive therapy to approved CNS stimulant medications in pediatric patients six years and older. The first non-stimulant ADHD medication, with nighttime dosing, adds to Tris Pharma’s established portfolio of leading ADHD therapies and reinforces company's commitment to individuals with ADHD.

Indica Labs Receives FDA Clearance for HALO AP Dx Digital Pathology Platform for Use with Hamamatsu Images Acquired with the NanoZoomer® S360MD Slide Scanner

Indica Labs, an industry leader in AI-powered digital pathology solutions, and Hamamatsu Photonics K.K., a pioneer in whole slide imaging systems, announce that the...

By using this website you agree to accept Medical Device News Magazine Privacy Policy